#China #Shanghai #Innovation #Antengene #Dr. Bing Hou

Antengene Appoints Dr. Bing Hou as Chief Scientific Officer

SHANGHAI and HONG KONG, May 19, 2026 /PRNewswire/ – Antengene Corporation Limited, a global innovator in biotechnology, proudly announces the appointment of Dr. Bing Hou as the new Chief Scientific Officer. This strategic move reaffirms the company's commitment to enhancing its research and development (R&D) framework, which is pivotal in addressing significant medical needs across various therapeutic areas, including autoimmune diseases, solid tumors, and hematological malignancies.

Dr. Hou's journey with Antengene began in 2019, and he has been an instrumental figure within the company's scientific leadership team, most recently serving as Vice President and Head of Discovery Science and Translational Medicine. His leadership has been essential in establishing a highly proficient discovery organization, propelling several self-developed initiatives towards clinical development, and forming proprietary platforms designed to foster future innovations. The recent appointment aligns perfectly with Antengene's goal of cultivating a robust R&D model emphasizing innovation and transformation in patient care.

Dr. Jay Mei, Antengene's Founder, Chairman, and CEO, expressed satisfaction with this appointment, highlighting Dr. Hou's significant impact on the company’s scientific strategy and the enhancement of its internal research capabilities. Under Dr. Hou's guidance, Antengene has successfully developed its proprietary AnTenGager® T-cell engager (TCE) platform, used broadly in targeting various diseases. Dr. Mei emphasized the importance of this platform, particularly the recent global license agreement with UCB for ATG-201, a cutting-edge TCE tailored for B cell-related autoimmune diseases, further establishing Antengene’s value in proprietary discoveries.

In his new role, Dr. Hou will spearhead Antengene's Drug Discovery, Translational Medicine, and Chemistry, Manufacturing, and Controls (CMC) operations. His focus will be on deepening the company's research capabilities and enhancing the portfolio of next-generation therapeutic candidates that meet unmet medical needs. Dr. Hou stated, “Joining Antengene in this capacity is both an honor and an excitment. I believe we have a strong opportunity to expand our innovative pipeline, which includes groundbreaking therapies targeting significant health challenges.”

Among the promising programs he aims to develop are specialized T cell engagers from the AnTenGager® platform, a bispecific antibody-drug conjugate designed for enhanced efficacy, and a pioneering bifunctional fusion protein aimed at addressing T cell-driven autoimmune diseases.

Dr. Ho's esteemed academic background includes a Ph.D. in Biomedicine from the University of Leeds, UK. He has authored numerous influential research papers in prestigious journals, filed over 40 patents related to novel therapeutic mechanisms, and played a vital role in advancing several first-in-class drug candidates through various clinical development phases.

Antengene Corporation Limited operates as a research-driven, commercial-stage biotech firm passionately focused on creating first-in-class and best-in-class therapies for ailments with dire unmet medical needs. Currently, its pipeline includes promising candidates like ATG-022 and ATG-101, alongside the innovative T cell engager programs powered by the AnTenGager® platform.

The AnTenGager® platform employs advanced TCE technology with unique bivalent binding characteristics, enhancing targeting in challenging therapeutic areas such as autoimmune diseases and oncology. To date, Antengene has achieved significant milestones, including 32 investigational new drug (IND) approvals and multiple new drug application (NDA) approvals across the Asia Pacific region. Its flagship asset, XPOVIO® (selinexor), is already approved in several key markets, showcasing Antengene's effectiveness in delivering transformative solutions to patients in urgent need.

As Antengene embarks on this next phase of growth, the company's stakeholder community is looking forward to the innovative leadership that Dr. Hou will bring to the table, aligning with their mission to transform treatment delivery to patients worldwide.